Associated Papers
SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.
Ruz-Caracuel I et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia, 2026
RET germline mutations drive tumorigenesis but not tumor aggressiveness in MEN 2.
Machens A et al.
Endocrine, 2026
Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers.
Prete A et al.
The Journal of Clinical Endocrinology and Metabolism, 2026
Design, synthesis, and activity evaluation of RET protein degradation based on PROTAC and HyTTD techniques.
Xu N et al.
Bioorganic & Medicinal Chemistry Letters, 2026
Highly sensitive profiling somatic mutations of thyroid cancer by nucleotide-enrichment-based MALDI-TOF MS assay.
Bai H et al.
Scientific Reports, 2026
A novel multimodal diagnostic framework integrating hyperspectral imaging and deep learning for predicting RET gene mutations in medullary thyroid carcinoma.
Yang Z et al.
Computer Methods and Programs in Biomedicine, 2026
Liquid Biopsy-Based RET Mutation Profiling to Guide RET Inhibitor Treatment in Sporadic Medullary Thyroid Carcinoma May Be Useful in Cases with High Tumor Burden and Progressive Disease.
Ciampi R et al.
Thyroid : Official Journal of the American Thyroid Association, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Waliany S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Comprehensive Transcriptome Profiling of Sporadic Medullary Thyroid Carcinomas.
Palumbo D et al.
Scientific Data, 2026
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
Interpreting the functional impact of genetic variants: The need for context qualifiers.
Martinelli S et al.
American Journal of Human Genetics, 2026
Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping.
Kasajima A et al.
Virchows Archiv : an International Journal of Pathology, 2026
Atypical presentation and association of medullary thyroid carcinoma: reports from a tertiary care center in Northwest India.
Chakraborty AM et al.
Endocrinology, Diabetes & Metabolism Case Reports, 2026
Efficacy and safety of pralsetinib in multiple endocrine neoplasia type 2-associated pheochromocytoma: a case report.
Chen S et al.
Therapeutic Advances in Endocrinology and Metabolism, 2026
Landscape of Phenotype-Genotype Correlations in Romanian Patients with Medullary Thyroid Carcinoma.
Stanescu LS et al.
Cancers, 2025
Molecular Characterization of Adult-Type Lower-Grade Glioma (WHO Grade 1-3) with Targeted Next-Generation Sequencing: A Retrospective, Single-Institution Experience.
Pinamonti M et al.
Journal of Clinical Medicine, 2025
The Prostate is a Common Site of Disease in Patients with MEN2B and Medullary Thyroid Carcinoma.
Kraft IL et al.
Endocrine-related Cancer, 2025
[Integration of Molecular, Genetic, and Surgical Evidence Into the Indication Criteria for Preventive Thyroid Surgery].
Kesruek H et al.
Zentralblatt Fur Chirurgie, 2025
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Real-world efficacy and safety of selpercatinib in RET-mutant medullary thyroid cancer at a Tertiary Referral Center.
Machlah YM et al.
European Journal of Endocrinology, 2025
Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteins.
Moccia M et al.
Scientific Reports, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Proposed framework for triage of putative germline variants detected via tumour genomic testing in UK oncology practice.
McVeigh TP et al.
Journal of Medical Genetics, 2025
Prevalence and genetics of "de novo" MEN2 syndromes.
Casalini R et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
Patient-derived medullary thyroid cancer organoids: a potential model for mechanistic studies on diagnostics and therapy.
Jager EC et al.
European Thyroid Journal, 2025
Four decades of the RET gene: From discovery to tumor-agnostic therapy.
Takahashi M
Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.
Schöffski P et al.
Esmo Open, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Scollon S et al.
Jco Precision Oncology, 2025
Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
Zhong J et al.
Journal of Medicinal Chemistry, 2025
Updated Recommendations for Pediatric Surveillance in Hereditary Endocrine Neoplasia Syndromes: Multiple Endocrine Neoplasias, Hyperparathyroidism-Jaw Tumor Syndrome, and Carney Complex.
Wasserman JD et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinib.
Fukuda N et al.
The Oncologist, 2025
Development and Performance Validation of a Comprehensive Liquid Biopsy Genotyping Panel for Pan-cancer Analysis.
Lim S et al.
Annals of Laboratory Medicine, 2025
Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials.
Gil-Bernabé S et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 2025
IGSF10 is a RET antagonist regulating Ewing sarcoma growth and GnRH neuron migration.
Jayabal P et al.
Cell Reports, 2025
Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.
Shariq OA et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions.
Julian L et al.
Biorxiv : the Preprint Server for Biology, 2025
Targeting RET in medullary thyroid cancer.
Newbold K et al.
Endocrine-related Cancer, 2025
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present).
Armstrong D et al.
Expert Opinion on Therapeutic Patents, 2025
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice.
Brandi ML et al.
The Lancet. Diabetes & Endocrinology, 2025
Massively parallel immunopeptidome by DNA sequencing provides insights into cancer antigen presentation.
Shi Q et al.
Nature Genetics, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.
Pagliarini RA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Activating RET Mutations Promotes Osteoblastic Bone Metastases in Medullary Thyroid Cancer.
Bagheri-Yarmand R et al.
Biorxiv : the Preprint Server for Biology, 2025